Moolec Science (MLEC) Gross Profit (2023 - 2024)
Moolec Science (MLEC) reported Gross Profit of -$674369.0 for Q4 2024, down 390.58% on a YoY basis from $232074.0 in Q1 2024, and down 4664.88% sequentially from $14773.0 in Q3 2024.
Moolec Science (MLEC) Gross Profit (2023 - 2024) Analysis & Trends
Moolec Science (MLEC) has 2 years of Gross Profit data on file, last reported at -$674369.0 in Q4 2024.
- For the quarter ending Q4 2024, Gross Profit fell 390.58% year-over-year to -$674369.0; the trailing twelve-month figure through Dec 2024 stood at -$639496.0 (changed N/A YoY), and the FY2024 full-year result was $472581.0, up 429.77% from the prior year.
- Gross Profit eased to -$674369.0 in Q4 2024, from $14773.0 in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $232074.0 in Q4 2023 to a low of -$674369.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Moolec Science | 5.21 Bn | 5.21 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -674,369.00 |
| Dec 31, 2024 | -674,369.00 |
| Sep 30, 2024 | 14,773.00 |
| Sep 30, 2024 | 14,773.00 |
| Jun 30, 2024 | -71,643.00 |
| Jun 30, 2024 | -71,643.00 |
| Mar 31, 2024 | 91,743.00 |
| Mar 31, 2024 | 91,743.00 |
| Dec 31, 2023 | 232,074.00 |
| Dec 31, 2023 | 232,074.00 |
| Sep 30, 2023 | 220,408.00 |
| Sep 30, 2023 | 220,408.00 |